Inogen Inc Stock Price, News & Analysis

Inogen (Nasdaq: INGN), a medical technology company specializing in innovative respiratory products for homecare, has announced its plans to report third quarter 2024 financial results on November 7, 2024, after market close. The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day.

Interested parties can join the call by dialing (877) 841-3961 for US domestic callers or (201) 689-8589 for non-US callers. A live audio webcast and archived recording will be available on the Inogen Investor Relations website. The webcast will be archived for 6 months, and a replay of the call will be accessible until November 14, 2024.

Inogen, Inc. (Nasdaq: INGN) has launched the Inogen® Rove 4™ Portable Oxygen Concentrator in the U.S. market. This innovative device offers:

• The highest oxygen output in the lightest weight 4-setting POC
• Up to 840ml/min of medical grade oxygen
• Weighs less than 3 lbs with standard battery
• Three battery configurations providing up to 5 hours and 45 minutes of operation
• Patented pulse-dose Intelligent Delivery Technology®
• Best-in-class expected service life of up to 8 years

The Rove 4 aims to empower patients with choices that may help them with normal activities of daily living. Kevin Smith, President and CEO, expressed excitement about the launch and its potential positive impact on patients requiring oxygen therapy.

Inogen (Nasdaq: INGN) has appointed Eric Pauls as Vice President of Sales, North America, effective September 3, 2024. Pauls joins from RQM+, where he was Chief Customer Officer. With over 20 years of experience in the respiratory care business, Pauls brings extensive expertise in driving growth and leading high-performing teams.

CEO Kevin Smith and CCO Gregoire Ramade expressed excitement about Pauls' addition to the team, highlighting his experience at Tactile Medical and Philips as valuable for expanding Inogen's product offerings and facilitating the U.S. rollout of Simeox. Pauls' background includes P&L management, business development, and portfolio expansion, making him well-suited to support Inogen's growth strategies in the respiratory products market.

Inogen (Nasdaq: INGN) reported its Q2 2024 financial results, showing a 6.1% increase in total revenue to $88.8 million. The growth was primarily driven by higher demand in international and domestic business-to-business sales. Gross margin improved to 48.1% from 40.7% in Q2 2023. However, the company still reported a GAAP net loss of $5.6 million, albeit reduced from $9.8 million in Q2 2023. Adjusted EBITDA turned positive at $1.3 million. Inogen maintains a strong financial position with $121.2 million in cash and no debt. The company projects full-year 2024 revenue between $325 million to $330 million, representing 3% to 5% growth over the previous year.

Inogen (Nasdaq: INGN), a medical technology company specializing in innovative respiratory products for homecare, has announced its plan to report second quarter 2024 financial results on August 6, 2024, after market close. The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day.

Interested parties can join the call via phone or listen to the live audio webcast through the News / Events page on Inogen's Investor Relations website. The webcast will be archived for 6 months, and a replay of the call will be available until August 13, 2024. Inogen continues to use its Investor Relations website to disclose material non-public information and comply with Regulation FD.

Inogen (Nasdaq: INGN) has announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President of Business Development, effective July 22, 2024. Smith brings nearly 30 years of experience in the medical technology and legal fields, having previously served at Sirtex Medical and Flexion Therapeutics. His extensive background in securities, business development, and intellectual property is expected to strengthen Inogen's legal and business strategy teams. CEO Kevin Smith emphasized the importance of Smith's role in maintaining the company's integrity and compliance.

Inogen, a medical technology company specializing in respiratory products, announced findings from a study published in Pulmonary Therapy. The research, sourced from France's national healthcare database (SNDS), analyzed over 244,000 long-term oxygen therapy patients from 2013-2020. Results demonstrated that portable oxygen concentrators (POCs), alone or combined with other oxygen modalities, improved survival rates and were cost-effective compared to stationary concentrators, compressed tanks, and liquid oxygen. Additionally, Inogen's higher mobility POC devices, with autonomy over 5 hours, showed better outcomes in survival, healthcare resource use, and related costs than lower mobility devices.

Inogen, Inc. (Nasdaq: INGN) announced their first quarter 2024 financial results, showing an 8.1% increase in total revenue to $78.0 million, accompanied by a total gross margin of 44.1%. The GAAP net loss was $14.6 million, with adjusted net loss at $10.4 million. Adjusted EBITDA was a negative $7.6 million. Inogen expects revenue for the second quarter of 2024 to be in the range of $81 million to $84 million. The company remains focused on revenue growth, profitability, and innovation to enhance their market position.